Quest Diagnostics Incorporated

128.17+0.1300+0.10%Vol 793.59K1Y Perf 13.73%
Jun 15th, 2021 16:03 DELAYED
BID126.49 ASK129.90
Open128.62 Previous Close128.04
Pre-Market- After-Market128.17
 - -  - -%
Target Price
146.80 
Analyst Rating
Moderate Buy 2.04
Potential %
14.54 
Finscreener Ranking
★★★★     54.83
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★★+     58.40
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★★     70.65
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
★★★+     48.39
Market Cap16.74B 
Earnings Rating
Sell
Price Range Ratio 52W %
63.00 
Earnings Date
22nd Jul 2021

Today's Price Range

127.01128.81

52W Range

103.26142.80

5 Year PE Ratio Range

11.6025.00

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Neutral
Performance
1 Week
0.53%
1 Month
-5.35%
3 Months
4.48%
6 Months
5.94%
1 Year
13.73%
3 Years
15.15%
5 Years
67.06%
10 Years
130.53%

TickerPriceChg.Chg.%
DGX128.170.13000.10
AAPL129.64-0.8400-0.64
GOOG2 520.66-6.3800-0.25
MSFT258.36-1.5300-0.59
XOM64.332.26003.64
WFC45.460.31000.69
JNJ164.49-0.8800-0.53
FB336.75-0.0200-0.01
GE13.540.07000.52
JPM155.18-2.3900-1.52
Financial StrengthValueIndustryS&P 500US Markets
1.50
1.80
0.40
0.69
16.20
Leverage Ratio 2.10
ProfitabilityValueIndustryS&P 500US Markets
40.40
24.70
28.40
15.90
18.25
RevenueValueIndustryS&P 500US Markets
10.34B
85.02
7.92
4.31
DividendsValueIndustryS&P 500US Markets
1.94
2.48
6.47
8.04
Payout ratio21.00
Earnings HistoryEstimateReportedSurprise %
Q01 20213.773.76-0.27
Q04 20204.284.484.67
Q03 20203.754.3114.93
Q02 20201.411.420.71
Q01 20200.830.9413.25
Q04 20191.601.674.38
Q03 20191.721.762.33
Q02 20191.691.732.37
Earnings Per EndEstimateRevision %Trend
6/2021 QR2.88-4.64Negative
9/2021 QR2.320.43Positive
12/2021 FY11.21-0.53Negative
12/2022 FY7.970.13Positive
Next Report Date22nd Jul 2021
Estimated EPS Next Report2.88
Estimates Count8
EPS Growth Next 5 Years %26.50
Volume Overview
Volume793.59K
Shares Outstanding130.64M
Trades Count13.41K
Dollar Volume203.62M
Avg. Volume1.29M
Avg. Weekly Volume796.08K
Avg. Monthly Volume1.09M
Avg. Quarterly Volume1.16M

Quest Diagnostics Incorporated (NYSE: DGX) stock closed at 128.17 per share at the end of the most recent trading day (a 0.1% change compared to the prior day closing price) with a volume of 794.35K shares and market capitalization of 16.74B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 49000 people. Quest Diagnostics Incorporated CEO is Stephen H. Rusckowski.

The one-year performance of Quest Diagnostics Incorporated stock is 13.73%, while year-to-date (YTD) performance is 7.55%. DGX stock has a five-year performance of 67.06%. Its 52-week range is between 103.26 and 142.8, which gives DGX stock a 52-week price range ratio of 63.00%

Quest Diagnostics Incorporated currently has a PE ratio of 9.70, a price-to-book (PB) ratio of 2.29, a price-to-sale (PS) ratio of 1.51, a price to cashflow ratio of 7.00, a PEG ratio of 2.32, a ROA of 13.41%, a ROC of 17.69% and a ROE of 28.11%. The company’s profit margin is 18.25%, its EBITDA margin is 28.40%, and its revenue ttm is $10.33 Billion , which makes it $85.02 revenue per share.

Of the last four earnings reports from Quest Diagnostics Incorporated, there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $2.88 for the next earnings report. Quest Diagnostics Incorporated’s next earnings report date is 22nd Jul 2021.

The consensus rating of Wall Street analysts for Quest Diagnostics Incorporated is Moderate Buy (2.04), with a target price of $146.8, which is +14.54% compared to the current price. The earnings rating for Quest Diagnostics Incorporated stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Quest Diagnostics Incorporated has a dividend yield of 1.94% with a dividend per share of $2.48 and a payout ratio of 21.00%.

Quest Diagnostics Incorporated has a Neutral technical analysis rating based on Technical Indicators (ADX : 7.39, ATR14 : 2.25, CCI20 : -65.61, Chaikin Money Flow : -0.19, MACD : -1.06, Money Flow Index : 64.82, ROC : -3.31, RSI : 42.94, STOCH (14,3) : 25.79, STOCH RSI : 1.00, UO : 39.69, Williams %R : -74.21), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Quest Diagnostics Incorporated in the last 12-months were: Catherine T. Doherty (Option Excercise at a value of $3 883 652), Catherine T. Doherty (Sold 66 928 shares of value $7 653 067 ), Daniel C. Stanzione (Sold 11 223 shares of value $1 417 459 ), Gail R. Wilensky (Option Excercise at a value of $352 391), Gail R. Wilensky (Sold 6 111 shares of value $770 120 ), Mark J. Guinan (Option Excercise at a value of $5 437 591), Mark J. Guinan (Sold 81 756 shares of value $9 840 673 ), Michael E. Prevoznik (Option Excercise at a value of $5 054 912), Michael E. Prevoznik (Sold 88 093 shares of value $11 294 916 ), Michael J. Deppe (Option Excercise at a value of $598 244), Michael J. Deppe (Sold 10 450 shares of value $1 306 250 ), Stephen H. Rusckowski (Option Excercise at a value of $19 420 720), Stephen H. Rusckowski (Sold 291 997 shares of value $35 039 640 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
6 (42.86 %)
5 (38.46 %)
4 (33.33 %)
Moderate Buy
1 (7.14 %)
1 (7.69 %)
1 (8.33 %)
Hold
7 (50.00 %)
6 (46.15 %)
6 (50.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
1 (7.69 %)
1 (8.33 %)
Summary RatingModerate Buy
2.04
Moderate Buy
2.27
Moderate Buy
2.38

Quest Diagnostics Incorporated

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of nearly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.

CEO: Stephen H. Rusckowski

Telephone: +1 973 520-2700

Address: 500 Plaza Drive, Secaucus 07094, NJ, US

Number of employees: 49 000

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

55%45%

Bearish Bullish

53%47%

Bearish Bullish

53%48%

News

Stocktwits